Company profile: MicuRx Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of novel antimicrobials for drug-resistant infections. Portfolio includes Contezolid (MRX-I), an oxazolidinone for complicated skin and soft tissue infections (targets MRSA, VRE); Contezolid acefosamil (MRX-4), an injectable oxazolidinone in Phase III; MRX-8, a polymyxin for multidrug-resistant Gram-negative; MRX-5, a boron compound; MRX-7, a pleuromutilin inhibitor; and MRX-15, a kidney-targeted therapy.
Products and services
- Contezolid (MRX-I): An oxazolidinone antibiotic, regulatory-approved, engineered to treat complicated skin and soft tissue infections caused by MRSA and VRE, targeting multidrug-resistant Gram-positive pathogens
- MRX-8: A polymyxin antibiotic, polymyxin-class, built to target multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa
- Contezolid acefosamil (MRX-4): An injectable oxazolidinone antibiotic, Phase III, created to treat complex skin and soft tissue infections targeting multidrug-resistant Gram-positive bacteria
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MicuRx Pharmaceuticals
Biocontrol
HQ: United Kingdom
Website
- Description: Provider of a novel system using biological agents to control bacterial infections by Pseudomonas aeruginosa, with proven efficacy and safety even where conventional antibiotics have failed.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocontrol company profile →
Xycrobe
HQ: United States
Website
- Description: Provider of early-stage biotechnology research and development leveraging extensive human microbiome data to develop novel therapies for clinical applications, with innovations that utilize microbes as delivery vehicles.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xycrobe company profile →
Kallyope
HQ: United States
Website
- Description: Provider of medicines developed using the science of gut-brain biology to transform human health.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kallyope company profile →
Assembly Bio
HQ: United States
Website
- Description: Provider of oral biologic therapeutics focused on antiviral drug development, including a next-generation capsid assembly modulator for HBV to disrupt replication and prevent new cccDNA, an HBV/HDV pipeline with small molecule inhibitors and interferon-α receptor agonists, and a herpesvirus portfolio targeting high-recurrence genital herpes and transplant-associated herpesviruses, with clinical trials of ABI-H3733 and ABI-4334.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Assembly Bio company profile →
Solarea Bio
HQ: United States
Website
- Description: Provider of microbial therapeutics and microbial-based solutions targeting chronic inflammation. Develops Defined Microbial Assemblage products combining probiotic microbes from fruits and vegetables with prebiotic fibers, advances medical foods, and creates synbiotics to protect against bone loss. Also offers licensing of its microbial-based technology, including a technology licensing agreement with ADM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Solarea Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MicuRx Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MicuRx Pharmaceuticals
2.2 - Growth funds investing in similar companies to MicuRx Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MicuRx Pharmaceuticals
4.2 - Public trading comparable groups for MicuRx Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →